Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients...
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of...
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key...
CHICAGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global...
FDA grants Priority Review to idebenone for Leber Hereditary Optic Neuropathy (LHON), a disease for which there are no existing...
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025...
Preeminent SOL-backed treasury vehicle - with potential to raise over $1.25 billion aggregate gross proceeds - unlocks capital markets to...
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines...
In this free webinar, gain insight into the core principles and current capabilities of non-covalent and covalent DNA-Encoded Library (DEL)...
New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially...
Leadership change positions NCQA for the next generation of quality improvement. WASHINGTON, DC / ACCESS Newswire / September 17, 2025...
BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel...
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) servicesMALVERN, Pa., Sept. 17, 2025...
The European Journal of Pediatrics publishes the first-ever multicenter clinical trial results demonstrating that the Vivos DNA appliance — part...
ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational...
New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin...
New formats redefine molecular assay development by cutting refrigeration costs, simplifying logistics, and ensuring uncompromised performance at room temperature. CINCINNATI,...
New formats redefine molecular assay development by cutting refrigeration costs, simplifying logistics, and ensuring uncompromised performance at room temperature. CINCINNATI,...
Children's Hospital of Philadelphia Researchers Find New Therapies Show Promise Against ALK-Driven Cancers PHILADELPHIA, Sept. 16, 2025 /PRNewswire/ -- Researchers...
Showcases SSi Mantra’s strengths in robotic telesurgery and opportunity in pediatricsFORT LAUDERDALE, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- SS...